Skip to main content
TipRanks
Go Ultimate75% OFF

Creo Medical (CREO) AI Stock Analysis

63 Followers
GB:CREO

Creo Medical

(LSE:CREO)

Select Model
Rating:41Neutral
Price Target:GBX 10.50â–²(2.44% Upside)
Action:reiterated
Date:10/01/26

Low score driven mainly by weak financials from losses and cash burn despite balance sheet resilience, compounded by bearish technicals and unattractive valuation on negative earnings.

Positive Factors
Manageable leverageRelatively low debt compared with equity gives Creo financial flexibility while it scales its medical-device business. This can help preserve capacity for commercial investment and product development, although the benefit depends on containing ongoing losses and cash use.
Negative Factors
Persistent operating lossesLarge recurring operating losses show that the current revenue base remains well below the scale needed to support Creo’s cost structure. Until core operations approach breakeven, growth may not translate into durable earnings and financial risk will remain elevated.

Creo Medical (CREO) vs. iShares MSCI United Kingdom ETF (EWC)

-20%0%20%40%60%80%GB:CREO0.00%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 46.04M
Dividend Yield
―
Average Volume (3M)
714.73K
Price to Earnings (P/E)
-2.3
Beta (1Y)
1.15
Revenue Growth
―
EPS Growth
―
Country
UK
Employees
104
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Creo Medical Business Overview & Revenue Model

Company Description

Creo Medical Limited, a UK-based enterprise and subsidiary of Creo Medical Group plc, specializes in the innovation and creation of electrosurgical medical devices for surgical endoscopy applications. Founded in 2003 as MicroOncology Ltd and headquar...

How the Company Makes Money

Creo Medical makes money primarily through the sale of medical devices and associated consumables used in endoscopic procedures. Key revenue streams include: (1) Capital equipment/platform sales: revenue from selling its electrosurgical generator/sys...

Creo Medical Financial Statement Overview

Summary

Balance sheet offers stability via low debt and positive equity, but income statement and cash flow reflect persistent losses, negative margins, and heavy cash burn with revenue volatility; 2025 rebound projected.

Income Statement

35Negative

Balance Sheet

65Positive

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.00M6.00M4.00M4.00M27.17M25.16M
Gross Profit1.90M1.40M1.90M15.30M10.01M9.02M
EBITDA-19.70M-19.70M-26.10M-20.70M-27.62M-27.54M
Net Income5.30M5.30M-28.70M-21.70M-26.94M-24.59M
Balance Sheet
Total Assets59.10M59.10M65.00M76.60M75.34M100.61M
Cash, Cash Equivalents and Short-Term Investments12.40M12.40M8.70M18.50M13.10M43.53M
Total Debt4.10M4.10M4.40M8.30M11.70M10.56M
Total Liabilities9.10M9.10M22.60M16.80M25.93M27.29M
Stockholders Equity50.00M50.00M42.40M59.80M49.40M73.32M
Cash Flow
Free Cash Flow-18.90M-20.00M-22.60M-22.80M-28.26M-32.10M
Operating Cash Flow-18.90M-19.10M-22.20M-21.60M-24.99M-25.98M
Investing Cash Flow19.40M19.40M15.30M-18.30M-6.03M-7.87M
Financing Cash Flow-700.00K-700.00K16.20M29.80M400.00K31.99M

Creo Medical Technical Analysis

Technical Analysis SentimentNegative
Last Price10.25

Price Trends

50DMA11.22Negative
100DMA12.34Negative
200DMA12.95Negative

Market Momentum

MACD-0.23Positive
RSI31.40Neutral
STOCH7.11Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CREO, the sentiment is Negative. The current price of 10.25 is below the 20-day moving average (MA) of 10.90, below the 50-day MA of 11.22, and below the 200-day MA of 12.95, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 31.40 is Neutral, neither overbought nor oversold. The STOCH value of 7.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CREO.

Creo Medical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:CREO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:TSTLGB:TSTL80OutperformGBP 188.69M23.5323.05%3.62%10.02%19.83%
GB:SNGB:SN72OutperformGBP 9.85B20.4512.25%2.50%2.17%27.33%
GB:AMSGB:AMS71OutperformGBP 617.83M166.761.44%1.65%6.05%-60.00%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:SUNGB:SUN45NeutralGBP 3.73M-4.00-15.47%―-3.68%20.00%
GB:CREOGB:CREO41NeutralGBP 46.04M-2.26-38.29%―――

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%GB:CREOGB:AMSGB:SUNGB:TSTLGB:SNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:CREO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:CREOCreo Medical10.250.000.00%
GB:AMSAdvanced Medical Solutions283.5073.4534.97%
GB:SUNSurgical Innovations Group Plc0.40-0.18-31.03%
GB:TSTLTristel plc392.5041.3611.78%
GB:SNSmith & Nephew (UK)1176.50-35.84-2.96%

Creo Medical Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and Financing

Creo Medical Cuts Costs and Lifts Revenue as Endoscopy Devices Gain Traction

Positive
Sep 30, 2026

Creo Medical reported unaudited interim results for the six months to 30 June 2026 showing strong progress in tightening its cost base while accelerating commercial adoption of its advanced endoscopy tools. Revenue rose 45% to £3.2 million, underlyin...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026